These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32725411)

  • 1. 10-Year Paclitaxel Dose-Related Outcomes of Drug-Eluting Stents Treated Below the Knee in Patients with Chronic Limb-Threatening Ischemia (The PADI Trial).
    Konijn LCD; Wakkie T; Spreen MI; de Jong PA; van Dijk LC; Wever JJ; Veger HTC; Statius van Eps RG; Mali WPTM; van Overhagen H
    Cardiovasc Intervent Radiol; 2020 Dec; 43(12):1881-1888. PubMed ID: 32725411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
    Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Drug-Eluting Stents for Infrapopliteal Lesions in Patients with Critical Limb Ischemia: The PADI Trial.
    Wakkie T; Konijn LCD; van Herpen NPC; Maessen MFH; Spreen MI; Wever JJ; Statius van Eps RG; Veger HT; van Dijk LC; Mali WPTM; van Overhagen H
    Cardiovasc Intervent Radiol; 2020 Mar; 43(3):376-381. PubMed ID: 31807849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia.
    Spreen MI; Martens JM; Knippenberg B; van Dijk LC; de Vries JPM; Vos JA; de Borst GJ; Vonken EPA; Bijlstra OD; Wever JJ; Statius van Eps RG; Mali WPTM; van Overhagen H
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial.
    Spreen MI; Martens JM; Hansen BE; Knippenberg B; Verhey E; van Dijk LC; de Vries JP; Vos JA; de Borst GJ; Vonken EJ; Wever JJ; Statius van Eps RG; Mali WP; van Overhagen H
    Circ Cardiovasc Interv; 2016 Feb; 9(2):e002376. PubMed ID: 26861113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
    Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia.
    Martens JM; Knippenberg B; Vos JA; de Vries JP; Hansen BE; van Overhagen H;
    J Vasc Surg; 2009 Sep; 50(3):687-9. PubMed ID: 19700099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jul; 66():595-600. PubMed ID: 31863948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia.
    Liistro F; Porto I; Angioli P; Grotti S; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    Circulation; 2013 Aug; 128(6):615-21. PubMed ID: 23797811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
    Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Snyder SA; O'Leary EE; Tepe G; Scheinert D; Zeller T;
    J Am Coll Cardiol; 2013 Jun; 61(24):2417-2427. PubMed ID: 23583245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
    Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
    Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Shishehbor MH; Li J; Wong VL; Harth KC; Cho JS; Kashyap VS
    J Vasc Surg; 2020 Sep; 72(3):968-976. PubMed ID: 31917036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sense and nonsense of bare metal stents below the knee.
    Caradu C; Brizzi V; Auque H; Midy D; Ducasse E
    J Cardiovasc Surg (Torino); 2016 Oct; 57(5):653-66. PubMed ID: 27177357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
    Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
    J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.